The Crystal Structure of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Provides the Structural Basis for Its Intrinsic Activity and the Short Half-life of TAFIa**

Received for publication, May 26, 2008, and in revised form, June 17, 2008 Published, JBC Papers in Press, July 31, 2008, DOI 10.1074/jbc.M804003200

Kanchan Anand1,2, Irantzu Pallares1,3, Zuzana Valnickova4, Trine Christensen4, Josep Vendrell4, K. Ulrich Wendt5, Herman A. Schreuder1,4, Jan J. Enghild5, and Francesc X. Avilés1

From the 1Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, 08193 Bellaterra (Barcelona), Spain, the 2Center for Insoluble Protein Structures (inSPIN) and Interdisciplinary Nanoscience Center (iNANO) Department of Molecular Biology, Aarhus University, DK-8000 Aarhus C Denmark, and the 3Sanofi-Aventis Pharma Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany

Mature thrombin-activable fibrinolysis inhibitor (TAFIa) is a highly unstable metallocarboxypeptidase that stabilizes blood clots by clipping C-terminal lysine residues from partially degraded fibrin. In accordance with its in vitro antifibrinolytic activity, animal studies have reported that inhibition of mature TAFI aids in the prevention of thrombosis. The level of TAFI activity is stringently regulated through (i) controlled proteolytic truncation of the zymogen (TAFI), generating the mature enzyme, TAFIa, and (ii) the short half-life of TAFIa. TAFI itself exhibits an intrinsic enzymatic activity, which is likely required to provide a baseline level of antifibrinolytic activity. The novel crystal structure presented here reveals that the active site of TAFI is accessible, providing the structural explanation for the its intrinsic activity. It also supports the notion that an “instability region” exists, in agreement with site-directed mutagenesis studies. Sulfate ions, bound to this region, point toward a potential heparin-binding site and could explain how heparin stabilizes TAFIa.

**This work was supported by Grants LSHG 2006-18830-CAMP from the EC-EF, Commission, Directorate F, Grant BIO2007-68046 from Ministry of Education and Science of Spain (for Universitat Autònoma de Barcelona), and a grant from the Danish Natural Science Research Council (for Aarhus University). H. A. S. and K. U. W. are employed by Sanofi-Aventis, a publicly held pharmaceutical company. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and structure factors (code 3DGV) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

1 These authors contributed equally to this work.
2 Present address: EMBL, Heidelberg, Structural and Computational Biology and Developmental Biology Unit 69117, Heidelberg, Germany.
3 Recipient of a fellowship from the PFIP Program (Spain).
4 To whom correspondence may be addressed: Herman A. Schreuder, Sanofi-Aventis Pharma Deutschland GmbH, Bldg. G877, Industriepark Höchst, 65926 Frankfurt am Main, Germany. Tel.: 49-6930516189; Fax: 49-6930580169; E-mail: herman.schreuder@sanofi-aventis.com.
5 To whom correspondence may be addressed: Jan J. Enghild, Center for Insoluble Protein Structures (inSPIN) and Interdisciplinary Nanoscience Center (iNANO) Dept. of Molecular Biology, Aarhus University, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark. Tel.: 45-89425062; Fax: 45-89425063; E-mail: jje@mb.au.dk.

Thrombin-activable fibrinolysis inhibitor (TAFI) (1), also known as plasma carboxypeptidase B (CPB), carboxypeptidase B2, carboxypeptidase R, or procarboxypeptidase U (2–4), is a member of the M14A subfamily of metallocarboxypeptidases (MEROPS data base; Ref. 5). It has been described as a fibrinolysis inhibitor that circulates in plasma as a plasminogen-binding protein. TAFI is involved in the fibrinolytic pathway and therefore seems to be highly regulated (6). It is a 60-kDa glycoprotein secreted by the liver with an isoelectric point of 5.0 (2). The glycans are mainly located on the pro-domain. They account for around 20% of the human TAFI mass and are assumed to play a role in stability and solubility (7). The pro-domain consists of a 92-residue N-terminal peptide, which can be removed by proteolysis, generating a 304-residue catalytic region called TAFIa (1–3).

The removal of this peptide takes place by proteolytic cleavage of a specific Arg-Ala peptide bond at the loop between the pro-domain and the catalytic moiety. These two residues are Arg-92–Ala-93, numbered according to the N terminus of TAFI. The scission and dissociation of the two moieties causes the pl to shift from ~5 to 8 for mature TAFIa, rendering the protein more basic and less soluble than TAFI (7). Several proteases, including trypsin, thrombin, and plasmin, are able to cleave the Arg-92–Ala-93 bond. In vivo, the thrombin/thrombomodulin complex is most likely responsible for generation of TAFIa, although plasmin may also be able to function in this manner (8). TAFIa down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin. Those lysine residues act as ligands for the lysine-binding sites of plasminogen and tissue-type plasminogen activator (9). Removal of the lysine residues attenuates the fibrin cofactor function in the activation of plasminogen by tissue-type plasminogen activator, resulting in the prevention of accelerated plasmin formation and subsequent down-regulation of fibrinolysis (10). Consequently, inhibition of TAFIa may potentiate thrombosis and thrombotic therapies (11). TAFIa has also been implicated in the regulation of the inflammatory response by inactivating complement-de-
rived inflammatory peptides (12). This enzyme is therefore considered an important biomedical target (13). TAFI shows around 40% sequence identity to several metallocarboxypeptidases of the M14A subfamily (Fig. 1), sharing with them the most important residues implicated in catalysis, zinc binding, and substrate binding (2, 14). It displays carboxypeptidase B (CPB)-like specificity, although, as mentioned above, it is designed to trim a polymeric natural protein substrate (fibrin) and not peptides like most of the CPB-like enzymes.

Following the removal of the pro-domain, the activity of TAFIa exhibits a short half-life, both in vivo and in vitro, with reported half-lives at 37 °C from 8 to 15 min (15). Due to its physiological role and the need for a very tight regulation of the blood coagulation cascade, it is likely that TAFIa has evolved to acquire its intrinsic instability, which ensures rapid inactivation at the site of action. The irreversible activity decay has been shown to be accompanied by structural changes of the enzyme (16–18). TAFIa can also be inactivated in vivo by further proteolytic degradation, indicating that other parts of the molecule become flexible and accessible. It was therefore suggested that the instability of the activity of TAFIa is due to intrinsic structural lability of the enzyme (19). This is quite unusual among metallocarboxypeptidases, which are generally very stable enzymes in the mature form (14).

The three-dimensional structure of TAFI described here is an advance in the long pursued structural knowledge. It will help to understand the instability of the mature enzyme and predict its ligands and ligand-binding sites. Significantly, these results reinforce a recent report of one of our groups (20) describing the significant intrinsic catalytic activity of TAFI and its potential capability to act in fibrinolysis, a function until recently exclusively assigned to its mature form, TAFIa.

**EXPERIMENTAL PROCEDURES**

**Protein Purification and Crystallization**—Bovine TAFI was purified using the same protocol as used for human TAFI (2, 21) and crystallized by hanging drop vapor diffusion at 18 °C using 8 mg/ml protein in 20 mM Tris-HCl, 120 mM NaCl at pH 7.4. Preliminary crystallization trials were conducted using the commercial Crystal Screen and Additive Screen I, II, and III (Hampton Research, Aliso Viejo, CA). The initial crystals were optimized using the micro-seeding technique. The best crystals, which were of bipyramidal shape, were obtained by using 100 mM Tris-HCl, pH 8.0, 1.5 M ammonium sulfate, 2% benzamidine as a precipitant with 10 μl of sodium malonate added to the reservoir the next day after setting up the drop. Crystals of dimensions approximately 0.3 × 0.25 × 0.3 mm3 grew in about 10 days. Crystallization plate setup using aged protein (of about 1 week) gave better quality crystals than those from freshly purified protein. Elucidation of optimal cryoconditions involved many trials with conventional cryoprotectants, none of which worked. Interestingly, a quick rinse in unrefined mustard oil (mustard seed oil) was more successful to bring the diffraction from 7 to 3.5 Å. Reannealing with 15% ethylene glycol and 2% glycerol resulted in diffraction beyond 2.5 Å. Crystals were immediately flash-cooled in liquid nitrogen. Data were collected from a single loop-mounted crystal held in a stream of cooled nitrogen gas at 100 K (Oxford Cryosystems). The crystals were fragile.
and suffered from radiation damage when exposed for longer times to X-rays. The data set up to 2.5 Å resolution (Table 1) were collected at station ID14-EH3 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) with an ADSC-q4 (Area Detector Systems Corp.) CCD detector. The data were processed using XDS and XSCALE (22).

Structure Solution and Refinement—The crystal structure was determined by molecular replacement using the software package Phaser (23). The catalytic domain of the refined structure of porcine proCPB (Protein Data Bank (PDB) code 1NSA; Ref. 24) was used as the search model. The space group was P4_2_2 with three TAFI molecules in the asymmetric unit, the solvent percentage is 66.7%, and V_m = 3.8 Å^2/Da. The molecular replacement procedure was non-trivial. Initial attempts found only two molecules that did not build a continuous crystal lattice. By allowing a large number of clashes, a third molecule was found that overlapped with the first molecule found. Only by asking Phaser to find four molecules was a third independent molecule found that completed the crystal packing. The search for the first molecule, which was repeated in all possible related space groups, gave a very clear signal: a single molecule was defined as in molecules I and II. The average temperature factors of the first two molecules are 47.2 and 51.7 Å^2, the average temperature factor of molecule II is similar to the electron density for molecule I. Although the first two molecules showed very good electron density, even for the pro-domain, which was not included in the search model, the electron density of the third molecule was very poor. Nevertheless, electron density consistently persisted when parts were omitted, and therefore, most of the third molecule was finally built as well, guided by the well defined structure of the first two molecules. Fig. 2 shows the final electron density map around the active site for the well defined molecule I and the less well defined molecule III. The electron density for molecule II is similar to the electron density for molecule I. Although the average temperature factors of the first two molecules are 47.2 and 51.7 Å^2, the average temperature factor of the third molecule was 120.9 Å^2. These values are very high but consistent with the overall B-factor of 57.3 Å^2 derived from the diffraction data using a Wilson plot. Glycosylation sites were observed at Asn-57A, Asn-69A, and Asn-92A of the pro-domain and a total of 15 N-acetylglucosamine, two fucose, and one mannoside molecules were fitted. No glycosylation was observed for Asn-129, which was reported to be glycosylated in human TAFI (7). Interestingly, this residue is completely buried in the TAFI structure. In addition, a large number of sulfate ions, 22 in total, were fitted, as well as three malonate molecules bound in the three independent active sites. In the Ramachandran plot as calculated with the program Molprobity (27), 1045
residues (89.9%) have \( \varphi \varphi \) angles in preferred regions, 76 (6.5%) in allowed regions, and 42 (3.6%) in disallowed regions. The final statistics are listed in Table 1. The structure factors and final coordinates have been deposited with the PDB under code 3DGV.

**RESULTS**

**Crystallization, Structure Determination, and Overall Structure**—Previously, systematic attempts from our groups to crystallize human TAFI and TAFIa failed due to the low recovery levels of the enzyme purified from human plasma. Attempts to produce crystals using TAFI purified from pooled human plasma were unsuccessful, possibly due to individual glycosylation differences resulting in a heterogeneous population of TAFI molecules. Consequently, we refocused our strategy toward the crystallization and x-ray structure determination of bovine TAFI, for which we were able to purify large amounts of homogeneously glycosylated material from the blood of a single animal. Bovine TAFI has 77% sequence identity and 86% sequence similarity to human TAFI (Fig. 1). In addition, as discussed below, sequence comparison suggests that the bovine form is more stable than the human, which would also facilitate crystallization. The generated bovine TAFI crystals diffracted to 2.5 Å and contained three protein molecules in the asymmetric unit. The generated bovine TAFI crystals diffracted to 2.5 Å and contained three protein molecules in the asymmetric unit. The generated bovine TAFI crystals diffracted to 2.5 Å and contained three protein molecules in the asymmetric unit. The generated bovine TAFI crystals diffracted to 2.5 Å and contained three protein molecules in the asymmetric unit. The generated bovine TAFI crystals diffracted to 2.5 Å and contained three protein molecules in the asymmetric unit.

**Crystal Structure of TAFI**

FIGURE 3. Packing of the three TAFI monomers in the asymmetric unit of our crystals. The two monomers on the left (orange/green and yellow/cyan) have extensive contacts and are packed as a dimer. Dimer contacts between these two monomers stabilize some regions (see “Results”), which are extremely flexible in the third monomer (top, right).

| Protein | Residues | Sequence Identity | Sequence Similarity |
|---------|----------|-------------------|---------------------|
| Bovine TAFI | 401 | 77% | 86% |
| Human TAFI | 394 | 90% | 90% |

Comparison with Human TAFI—Sequence alignment of human and bovine TAFI (Fig. 1) and three-dimensional fitting of the structure derived in this study revealed three clusters of low sequence homology. The first cluster, residues Lys-92–His-96 and Lys-101–Met-103, is located in the loop between helices \( \alpha2 \) and \( \alpha3 \) and between helix \( \alpha3 \) and strand \( \beta4 \). The second cluster, residues Leu-132–Lys-135, is located in the long loop between helices \( \alpha4 \) and \( \alpha5 \). These clusters are all in solvent-exposed loops, and it is not clear whether they have func-
tional significance. The last cluster involves residues Asn-232–Ile-236 and is right in the middle of the instability region (see below). Mutations to Ile in two residues of this cluster at positions 233 and 236 (Table 2) are in human TAFI associated with increased stability. Since bovine TAFI displays Ile at both positions, it is expected to be more stable than human TAFI; this may in part explain why the bovine form is able to crystallize, whereas the human counterpart is not.

Glycosylation Sites—Our electron density maps provided clear evidence for attached carbohydrates at Asn-28A, Asn-57A, Asn-69A, and Asn-92A, all in the pro-domain, although they do not allow a full description of the glycan structures. Equivalent carbohydrate attachment sites have been previously identified in human TAFI by one of our groups (7). A fifth carbohydrate site at Asn-129, identified in the same report in the catalytic domain of human TAFI, could not be confirmed in our bovine TAFI crystal structure, where Asn-129 is buried and cannot be glycosylated.

The Active Site—The active site catalytic machinery follows the same arrangement described for all A/B type M14 metallo-carboxypeptidases; the catalytic zinc ion is pentahedrally coordinated by His-69 Nδ1, His-196 Nδ1, and both Oe1 and Oe2 of Glu-72 and O3 of the bound malonate that occupies the position normally occupied by a solvent water molecule polarized by the side chain of the general base, Glu-270. Further residues traditionally identified as responsible for substrate binding and catalysis (Arg-71, Arg-145, Arg-127, Ser-197, Tyr-198, Ser-199, Tyr-248, and Glu-270) are found in equivalent positions. The CPB-like specificity toward basic residues of TAFIa is expected to be mainly determined by the acidic residue Asp-255 typically present in B forms at this position in the crystal structure (24, 28). The active site of TAFI is in the active conformation, similar to e.g. proCPB, where the conformation of the catalytic domain within the proenzyme is identical to the conformation of the catalytic domain in the activated form (24). Interestingly,

![FIGURE 5. Comparison of bovine TAFI and porcine proCPB.](image)

**TABLE 2**

Selected human TAFI variants with longer half-lives as wild-type

| Mutation* | \( t_{1/2} \) | WT | Mutant/WT | Ref. |
|-----------|-------------|----|-----------|-----|
| T233I     | 15 min     | 8 min | 1.9 | A   |
| T233I     | 9.4 min    | 6.3 min | 1.5 | B   |
| T233I-T236I | 15 min  | 6.3 min | 2.4 | B   |
| T233I-S213C | 70 min   | 6.3 min | 11.1 | B     |
| T233I     | 18 min     | 12 min | 1.5 | C   |
| L261Q     | 16 min     | 12 min | 1.3 | C   |
| K55N-H242Q | 31 min   | 12 min | 2.6 | C   |
| I139T-H242P | 31 min    | 12 min | 2.6 | C   |
| H68F-H242A | 55 min    | 12 min | 4.6 | C   |
| H240Y     | 47 min     | 12 min | 3.9 | C   |
| K55N-H201R-S213C-H242P | 4.4 h | 0.2 h | 22 | C |
| S213C-S234N-H242Q | 2.9 h | 0.2 h | 15 | C |
| H240Y-H242Q | 3.0 h | 0.2 h | 15 | C |
| S213C-H240Y | 4.3 h | 0.2 h | 22 | C |
| T233I-H240Y-H242Q | 3.5 h | 0.2 h | 18 | C |
| S213C-H240Y-H242Q | 26 h | 0.2 h | 130 | C |
| S213C-T233I-T236I-H240Y-H242Q | 19 h | 0.1 h | 181 | D |

* Numbering adapted to the scheme of Figure 1.

Since the measured \( t_{1/2} \) is dependent on the exact assay conditions, we have listed for each mutant the wild-type \( t_{1/2} \) measured under exactly the same conditions. The ratio mutant \( t_{1/2} \) to WT \( t_{1/2} \) should be more or less independent of the details of the assay.

References: A; Schneider et al. (31), B; Ceresa et al. (32), C; Knecht et al. (33), D; Ceresa et al. (34).
the active site of proCPB is blocked by a salt bridge between Asp-41A in the pro-domain and Arg-145. In contrast, this interaction is absent in TAFI because the residue equivalent to the aspartate in proCPB is here a valine, unable to make a salt link. Considering that the TAFI pro-domain is ~1.2 Å farther away from the catalytic domain as compared with proCPB due to the 12° rotation described above, it may be feasible that TAFI (zymogen) is able to accommodate substrates. Biochemical evidences (20, 30) indicate that, in contrast to other B forms, TAFI possesses a significant intrinsic proteolytic activity (20). This experimental observation can now be rationalized in view of the structural determinants described here. TAFI displays a wide channel, significantly larger and more open than in the zymogen forms of other carboxypeptidases and lacks the Asp-41A–Arg-145 salt bridge that blocks the active site, both features nicely explaining its intrinsic activity.

A malonate molecule from the crystallization buffer was found bound to the active site in the crystal structure (Figs. 2, 4, and 5). One of the carboxylate groups of the malonate interacts with the catalytic zinc; the other interacts with the side chains of Arg-127 and Arg-145. The same binding sites are used by the peptide substrates (14), further illustrating that the active site is unblocked in our TAFI structure.

The Instability Region—TAFIa is unstable with a half-life of about 10 min at 37 °C (15), and it is thought that this instability plays an important physiological function. Extensive site-directed mutagenesis has been carried out to clarify this issue, and several of the most relevant results are summarized in Table 2. One of the conclusions of these studies points out to the instability of TAFIa primarily being due to a conformational change and not to proteolytic degradation (17). Natural variants and mutagenesis studies of human TAFI revealed a number of residues that influence the stability of TAFIa (31–34) and are concentrated in the region Ser-213–His-242, which encompasses helix α6 and strand β7 (Fig. 1, and in Fig. 4, the regions colored orange). In this respect, it is noteworthy that the naturally occurring T233I variant in bovine TAFI almost doubles the half-life of human TAFIa (31–34). In molecules I and II, in the asymmetric unit of our structure of bovine TAFI, the equivalent region is involved in dimer contacts with the pro-domain of a neighboring molecule and is well defined in the electron density maps. However, in molecule III, where this region is not tethered by crystal contacts, it is the region of the catalytic domain with the highest temperature factors in excess of 130 Å² (Fig. 6). The first half of what would be strand β7 in the other molecules is completely disordered. Interestingly, this high temperature factor/disordered region contains 7 of the 12 amino acids in Table 2, which are shown to influence the stability of TAFIa. Combining five stabilizing mutations in this region, Ceresa et al. (34) obtained a dramatic 180-fold increase in the half-life of TAFIa. We therefore postulate that TAFIa inactivation starts in this region, which evolves from a partially disordered to a fully disordered state followed by the unfolding of the remaining parts of the protein. We thus propose to call this region the instability region of TAFI. Further support for this instability region is given below in the section on the heparin-binding site.

A Potential Heparin-binding Site?—The 22 bound sulfate ions contained in our crystal structure (Fig. 4) were analyzed in detail in the search for a putative heparin-binding site. Mao et al. (8) report that glycosaminoglycans (heparin) have two effects on TAFI: (i) an increase in generation of TAFIa by plasmin and (ii) a 2.3-fold increase in the half-life of TAFIa at 25 °C, from 74 to 170 min. Based on a sequence analysis, the same authors discovered that the sequence Trp-120–Ser-131 was homologous to the heparin-binding sequence in GAG proteins and postulated this site to be the heparin-binding site of TAFI. However, in our structure, only one sulfate in molecule III was bound to the NZ of Lys-122 at this site and none in molecules I and II.

In contrast, five sulfate ions were found to be bound to the instability region (Ser-213–His-242; region a; Fig. 4; gold sulfates) in molecule I, and three of them were also found at the same position in molecule II. The first sulfate is bound to His-234 and Arg-235 at the C terminus of helix α6 as well as to the side chain of Lys-276 of a neighboring molecule. This site is next to position 233, where the lle variant is twice as stable as the Thr variant. The second sulfate is bound to Arg-237 and close to the side chains of Glu-49A at the pro-region. Residues Arg-224 and His-240 at about 5 Å distance provide additional charge compensation. Coincidentally, mutations of His-240 were identified by random mutagenesis to influence the half-life of TAFIa. The third sulfate is bound to the side chains of His-216, Ser-220, and Arg-224. Arg-237 and Lys-276 of a neighboring TAFI molecule bind the fourth sulfate. Finally, the fifth sulfate is bound to the side chain of Lys-214 but is closer to a neighboring TAFI molecule.

Another chain of bound sulfates is running from the instability region toward the active site cleft (region b; Fig. 4, magenta sulfates). However, a heparin chain bound in this position is likely to hinder substrate binding and therefore contradict biochemical
Crystal Structure of TAFI

data. Finally, five sulfate ions are bound at three sites near the very basic top of the pro-domain (region c, Fig. 4, blue sulfates); although this region is a potential heparin-binding site, it cannot explain the stability increase of TAFIa where the pro-domain is absent. Since heparin binding to region b in the active site cleft is likely to hinder catalytic activity and heparin binding to region c in the pro-domain is unable to influence the stability of TAFIa (pro-domain-free TAFI), we conclude that region a is the most likely heparin-binding site. Since region a coincides with the instability region, this finding could well explain the observed increase in TAFIa stability after heparin binding.

DISCUSSION

The crystal structure presented here firmly establishes that the fold of bovine TAFI and, because of the very high sequence similarity, also of human TAFI, is similar to the fold of proCPB, except for the position of the pro-domain shielding the access to the catalytic site. Two of the three independent molecules in the asymmetric unit, I and II, form a dimer and are well defined in the electron density maps since their flexible parts are fixed by dimer contacts. By contrast, molecule III is not stabilized by equivalent contacts and shows significant disorder, with average temperature factors in the range between 75 and 160 Å². We kept this molecule in our crystallographic model because its electron density consistently persisted, even after refinement with molecule III deleted. The disorder is influenced by the crystal packing but may also be partially caused by the instability of TAFIa. It is interesting to notice that the instability region, as defined by mutagenesis studies (31–34), fully coincides with the region with the highest temperature factors in the catalytic domain of molecule III. The pro-domain of this molecule has even higher temperature factors (Fig. 6), which appear to be caused by a hinge-bending movement.

Several bound sulfate ions were identified in the TAFI crystal structure, indicating the existence of a heparin-binding site. Only one sulfate ion was bound to the residues Trp-120–Ser-131 previously proposed as a heparin-binding site (8). In addition, this region is mainly buried as shown, for instance, by Arg-127. This residue is located in the active-site pocket and is believed to play an important role in catalysis. Consequently, residues Trp-120–Ser-131 are not likely to represent the TAFI heparin-binding site. In contrast, five sulfate ions were bound to the instability region, and heparin binding here may stabilize this region, leading to the 2.3-fold increase in $\epsilon_0$ of TAFIa as described previously (8). One should bear in mind, however, that the evidence presented here is indirect and that additional evidence (mutagenesis studies, cocrystal structure) are necessary to establish the heparin-binding site with certainty.

We observed four glycosylated sites in the pro-domain, which have also been detected in human TAFI using mass spectrometry in the mature catalytic domain of the human form, is not glycosylated in the bovine structure. The corresponding residue, Asn-129, is conserved but buried, suggesting that the folding of this region is different in the two despite their similar protein sequences.

The finding of a malonate molecule bound in a substrate-like manner in the potential active site of TAFI, the lack of a salt bridge locking the active site, and its open structure toward the solvent are interesting properties that might merit further investigation. They are in agreement with a recent report that indicates that human TAFI displays a surprisingly high intrinsic activity toward standard substrates of B-like enzymes and large peptides and a significant fibrinolytic activity (20, 30). Since TAFIa has a half-life in blood of only minutes, it seems quite reasonable to consider the possibility that TAFI, which is much more stable and soluble (7), plays a complementary (or even a direct) role in the antifibrinolytic function assigned to the enzyme. Now, a structural basis is provided for this hypothesis. Therefore, the structure here derived might not only help in better drug design strategies but also influence some of the foundations for the design and refinement of drugs and therapeutical strategies based on the potential binding and functional abilities of TAFI. We hope that this work might stimulate further efforts toward these or related research lines.

REFERENCES

1. Bajzar, L., Manuel, R., and Nesheim, M. E. (1995) J. Biol. Chem. 270, 14477–14484
2. Eaton, D. L., Malloy, B. E., Tsai, S. P., Henzel, W., and Drayna, D. (1991) J. Biol. Chem. 266, 21833–21838
3. Hendriks, D., Wang, W., Scharpe, S., Lommaert, M. P., and van Sande, M. (1990) Biochim. Biophys. Acta 1034, 86–92
4. Wang, W., Hendriks, D. F., and Scharpe, S. S. (1994) J. Biol. Chem. 269, 15937–15944
5. Rawlings, N. D., Morton, F. R., and Barrett, A. J. (2006) Nucleic Acids Res. 34, D270–272
6. Bouma, B. N., Marx, P. F., Mosnier, L. O., and Meijers, J. C. (2001) Thromb. Res. 101, 329–354
7. Valnickova, Z., Christensen, T., Skotrup, T., Thogersen, I. B., Hojrup, P., and Enghild, J. J. (2006) Biochemistry 45, 1525–1535
8. Mao, S. S., Cooper, C. M., Wood, T., Shafer, J. A., and Gardell, S. J. (1999) J. Biol. Chem. 274, 35046–35052
9. Suenson, E., Lutzen, O., and Thorsen, S. (1984) Eur. J. Biochem. 140, 513–522
10. Redlitz, A., Nicolin, F. A., Malycky, J. L., Topol, E. J., and Plow, E. F. (1996) Circulation 93, 1328–1330
11. Zirlik, A. (2004) Thromb. Haemostasis 91, 420–422
12. Campbell, W. K., Okada, N., and Okada, H. (2001) Immunol. Rev. 180, 162–167
13. Willemsen, J. L., and Hendriks, D. F. (2007) Front Biosci. 12, 1973–1987
14. Arolas, J. L., Vendrell, J., Aviles, F. X., and Fricker, L. D. (2007) Curr. Pharm. Des. 13, 349–366
15. Bozza, M. B., Wang, W., Bajzar, L., and Nesheim, M. E. (1998) J. Biol. Chem. 273, 2127–2135
16. Bozza, M. B., Bell, R., Stevens, W. K., and Nesheim, M. E. (2000) J. Biol. Chem. 275, 12868–12878
17. Marx, P. F., Hackeng, T. M., Dawson, P. E., Griffin, J. H., Meijers, J. C., and Bouma, B. N. (2000) J. Biol. Chem. 275, 12410–12415
18. Nesheim, M. (2003) Chest 124, 335–395
19. Marx, P. F., Bouma, B. N., and Meijers, J. C. (2002) Biochemistry 41, 1211–1216
20. Valnickova, Z., Thogersen, I. B., Potempa, J., and Enghild, J. J. (2007) J. Biol. Chem. 282, 3066–3076
21. Valnickova, Z., Thogersen, I. B., Christensen, S., Chu, C. T., Pizzo, S. V., and Enghild, J. J. (1996) J. Biol. Chem. 271, 12937–12943
22. Kabash, W. (1993) J. Appl. Crystallogr. 26, 795–800
23. Srononi, L. C., McCoy, A. J., and Read, R. J. (2004) Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 432–438
24. Coll, M., Guasch, A., Aviles, F. X., and Huber, R. (1991) EMBO J. 10, 1–9
25. Bruner, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonon, T., and Warren, G. L. (1998) Acta
Crystal Structure of TAFI

26. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Acta Crystallogr. Sect. D Biol. Crystallogr. 53, 240–255
27. Davis, I. W., Leaver-Fay, A. L., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., III, Snoeyink, J., Richardson, J. S., and Richardson, D. C. (2007) (2007) Nucleic Acids Res., 35, W375–W383
28. Garcia-Saez, I., Reverter, D., Vendrell, J., Aviles, F. X., and Coll, M. (1997) EMBO J. 16, 6906–6913
29. Vendrell, J., Querol, E., and Aviles, F. X. (2000) Biochim. Biophys. Acta 1477, 2884–2898
30. Willemse, J. L., Polla, M., and Hendriks, D. F. (2006) Anal. Biochem. 356, 157–159
31. Schneider, M., Boffa, M., Stewart, R., Rahman, M., Koschinsky, M., and Nesheim, M. (2002) J. Biol. Chem. 277, 1021–1030
32. Ceresa, E., Van de Borne, K., Peeters, M., Lijnen, H. R., Declerck, P. J., and Gils, A. (2006) J. Biol. Chem. 281, 15878–15883
33. Knecht, W., Willemse, J., Stenhamre, H., Andersson, M., Berntsson, P., Furebring, C., Harrysson, A., Hager, A. C., Wissing, B. M., Hendriks, D., and Cronet, P. (2006) FEBS J. 273, 778–792
34. Ceresa, E., De Maeyer, M., Jonckheer, A., Peeters, M., Engelborghs, Y., Declerck, P. J., and Gils, A. (2007) J. Thromb. Haemostasis 5, 2105–2112